- This event has passed.
Rejuvenation biotechnology: why age may soon cease to mean aging
5 November 2018 | 18:00 - 20:00
£3Event Navigation
This event is held in the Pfizer lecture theatre in the Cambridge University Chemistry Department and will be followed with a wine and cheese reception.
‘I’d say there is a 50/50 chance we will have brought ageing under decisive control within 20 years. In 100 years, there’s an 80% or 90% chance that we will have achieved that goal’ – Dr Aubrey de Grey in The Guardian, September 2018. Dr De Grey is the Chief Science Officer of the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, a Silicon Valley based non-profit whose goal is to ‘transform the way the world researches and treats age-related diseases’. to He is editor-in-chief of the journal Rejuvenation Research, a co-author of the book Ending Aging, and a Vice-President at AgeX, a biotech company applying cellular medicine to age-related diseases. De Grey contends that the fundamental knowledge to develop anti-aging medicines already exists.
‘I’d say there is a 50/50 chance we will have brought ageing under decisive control within 20 years. In 100 years, there’s an 80% or 90% chance that we will have achieved that goal’ – Dr Aubrey de Grey in The Guardian, September 2018. Dr De Grey is the Chief Science Officer of the Strategies for Engineered Negligible Senescence (SENS) Research Foundation, a Silicon Valley based non-profit whose goal is to ‘transform the way the world researches and treats age-related diseases’. to He is editor-in-chief of the journal Rejuvenation Research, a co-author of the book Ending Aging, and a Vice-President at AgeX, a biotech company applying cellular medicine to age-related diseases. De Grey contends that the fundamental knowledge to develop anti-aging medicines already exists.
